Atlanta, GEORGIA, United States
Atlanta, GEORGIA, United States

Zeno of Citium was a Greek thinker from Citium , Cyprus. He was possibly of Phoenician descent,. Zeno was the founder of the Stoic school of philosophy, which he taught in Athens from about 300 BC. Based on the moral ideas of the Cynics, Stoicism laid great emphasis on goodness and peace of mind gained from living a life of Virtue in accordance with Nature. It proved very successful, and flourished as the dominant philosophy from the Hellenistic period through to the Roman era. Wikipedia.


Time filter

Source Type

News Article | February 22, 2017
Site: www.marketwired.com

VALENCIA, SPAIN--(Marketwired - Feb 22, 2017) - Zenosense, Inc. ( : ZENO) ("Zenosense", the "Company"), a healthcare technology company primarily focused on the development and commercialization of MIDS Cardiac™, a Point of Care ("POC") handheld device for the early detection of certain cardiac event biomarkers to significantly accelerate the triage, diagnosis, treatment and disposition of patients reporting chest pain and with suspected acute myocardial infarction (heart attack), is pleased to announce that MIDS Medical Limited ("MML"), our joint venture based at Sci-Tech, Daresbury, has completed construction of two bench readers designed to test two methods of magnetic nanoparticle detection. Following an initial bench rig evaluation phase in Q4, 2016 MML has designed and constructed two types of rigs to test its two related nano-magnetic detection systems; these rigs are designed to gather preliminary, definitive quantitative data under highly controlled conditions. Priority testing has now commenced on the first of these rigs, a second iteration design designed to simulate MML's "Lab-on-Chip" detection method, whereby nanoparticles are dosed into wells on a "Test Slide" and located highly accurately in very close proximity to Hall effect magnetic sensors. This patented design is envisaged to be embodied in a commercial test strip where the Hall sensors will be integrated in a disposable test strip, the Hall sensors then being permanently and accurately located. Testing is designed to methodically measure the detective ability of the MIDS system: Firstly, pure Magnetite nanoparticles in the sub-200 nanometer to 1 micrometer range are being tested. These particles are dosed in liquid suspension into the test slide wells in defined multi-nanolitre sized volumes. MML subsequently plans to test modern composite magnetic beads in the 1 to 3 micrometer range, such as those used in high sensitivity troponin assays. Initial testing of very small volumes of very small pure Magnetite nanoparticles has already produced encouraging results, with relatively large and clean detective signals being recorded. Based on these first results, MML expects it will be able to similarly detect magnetic beads which may have a lower magnetic signal density but higher individual volumes. MML expects refinements will be made to this simulation rig, to further improve reproducibility of results and to better inform design, prior to the production of a prototype Lab-on-Chip test strip. A round of testing to a similar protocol is also planned on the second rig. This is a first iteration construction designed to explore the viability of a "Magnetic Bridge" structure for which MML submitted a patent application on January 19, 2017. We believe that, in addition to cardiac markers, the MIDS technology platform can be applied across a wide spectrum of diagnostic tests. Proof of detection is the first step in applying the MIDS technology to cardiac markers and other immunoassay tests. The Company believes there is an enormous potential market for highly accurate cardiac marker assays conducted by a hand held device at the POC. The Company's target is to develop a hand-held device which can achieve Gold Standard laboratory accuracy or better, with results delivered at the POC within minutes. About Zenosense, Inc. Zenosense Inc.'s primary focus, through our joint venture ownership in MIDS Medical Ltd., is the development of a cost-effective, hand-held Point of Care rapid cardiac diagnostic device, MIDS Cardiac™, and is also the holder of an exclusive global license agreement to develop and market effective medical devices for use in hospitals and primary healthcare settings targeting the early detection of both deadly bacteria and certain cancers in the exhaled breath of patients. To find out more about Zenosense ( : ZENO), visit our website at www.zenosense.com. Forward-Looking Statements Statements in this news release that are not statements of historical fact are forward-looking statements, which are subject to certain risks and uncertainties. Forward-looking statements can often be identified by words such as "expects," "intends," "plans," "may," "could," "should," "anticipates," "likely," "believes" and words of similar import. Forward-looking statements are based on current facts and analyses and other information that are based on forecasts of future results, estimates of amounts not yet determined and assumptions of management. Actual results may differ materially from those expressed or implied by forward-looking statements due to a variety of factors that may or may not be foreseeable or within the reasonable control of the Company. Readers are cautioned not to place undue reliance on such forward-looking statements. Additional information on risks and other factors that may affect the business and financial results of the Company can be found in filings of the Company with the U.S. Securities and Exchange Commission, including without limitation the section entitled "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2015 filed on filed on May 23, 2016, and in Company reports filed subsequently thereto. Except as otherwise required by law, the Company disclaims any obligations or undertaking to publicly release any updates or revisions to any forward-looking statement contained in this news release to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based. Respective statements concerning the development of both MIDS Cardiac™ and other devices under development have been made based on information obtained from MIDS Medical Ltd. and Zenon Biosystem, which the Company believes to be accurate, but have not been independently verified.


News Article | February 21, 2017
Site: www.accesswire.com

NEW YORK, NY / ACCESSWIRE / February 21, 2017 / Traders News Source, a leading independent equity research and corporate access firm focused on small and micro-cap public companies, is covering Zenosense, Inc. (OTCQB: ZENO) today. On January 23, 2017, ZENO announced a New Patent Application for an Additional MIDS Detection Method. The company announced that MIDS Medical Limited ("MML"), its 40% owned joint venture based at Sci-Tech, Daresbury, UK, has submitted a UK Intellectual Property Office patent application for an additional MIDS detection method. MML is in the process of proving detection in two purpose built bench rigs, the mechanical and electronic parts of which have been largely manufactured and are in assembly. MML believes that both detection methods are ground breaking and commercially viable, should either be proven as feasible to embody in a POC device. Zenosense's joint venture, market potential, and fundamentals are available here: READ MORE ZENO has minimal assets, rising short term debt, and no revenues to date. It reported a net loss of $135,535 for third quarter 2016, compared to a net loss of $134,775 million during the same period in the prior year. We are taking a look at estimates of when ZENO may begin producing revenue here: READ MORE Traders News Source LLC (TNS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering small and micro-cap equity markets. TNS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles, and reports covering equities listed on NYSE, NASDAQ, and OTC exchanges. The other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. TNS has not been compensated, directly or indirectly, for producing or publishing this document. The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a chartered financial analyst. For further information on analyst credentials, please email [email protected]. Vikas Agrawal, a CFA® charter holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information, which is believed to be reliable. Content is researched, written, and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author per the procedures outlined by TNS. TNS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents, or reports. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way. TNS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake, or shortcoming. No liability is accepted whatsoever for any direct, indirect, or consequential loss arising from the use of this document. TNS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, TNS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness, or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TNS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.tradersnewssource.com. For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer be featured on our coverage list, contact us via email between 09:30 EST to 16:00 EST from Monday through Friday at: [email protected]. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


News Article | October 31, 2016
Site: www.marketwired.com

VALENCIA, SPAIN--(Marketwired - Oct 31, 2016) -  Zenosense, Inc. ( : ZENO) ("Zenosense", the "Company"), a healthcare technology company primarily focused on the development and commercialization of MIDS Cardiac™, a Point of Care ("POC") handheld device for the early detection of certain cardiac event biomarkers to significantly accelerate the triage, diagnosis, treatment and disposition of patients reporting chest pain and with suspected acute myocardial infarction ("heart attack"), here provides an update on the bench reader development. MIDS Medical Limited ("MML"), our 40% joint venture based at Sci-Tech, Daresbury, UK has provided the Company with a report on progress of the development of MIDS Cardiac™, the first development of MIDS, a POC technology intended to deliver medical laboratory analyser accuracy in a hand held device around the size of a smartphone. The patented MIDS technology works by detecting the magnetic signature of magnetic immunoassay nanoparticles, rather than most conventional technologies which typically optically detect a colorimetric signal, often photo luminescent, from those particles. MML and the Company believe that the MIDS nano magnetic detection system can be applied to a wide range of diagnostic immunoassay tests. This is expected to deliver far higher levels of sensitivity and accuracy at the POC, with the added advantages of a fully automated test from a small finger prick blood sample. MIDS Cardiac is aimed, in the first instance, at POC high sensitivity ("HS") troponin tests to diagnose heart attack at an early stage, or the absence of that event. Phase 1 of the MIDS Cardiac development is intended to produce a bench reader system to prove the principle of detection and to enable the development of a "lab-on-chip" test strip. MML reports that electronics design of the first iteration of the bench reader is complete, and that a printed circuit board to that design has been produced and populated with the testing components. This includes highly sensitive "Hall Effect" sensors, a magnetic field induction system and the amplification and noise reduction elements, necessary to detect the nano magnetic signatures of the target assay particles. Initial testing is expected to commence shortly. The results are expected to inform MML as to the design of a second iteration bench reader which is intended to refine the electronics, sensor positioning and physical magnetic systems prior to a more extensive phase of testing. Zenosense Inc.'s primary focus, through our joint venture ownership in MIDS Medical Ltd., is the development of a cost-effective, hand-held Point of Care rapid cardiac diagnostic device, MIDS Cardiac™, and is also the holder of an exclusive global license agreement to develop and market effective medical devices for use in hospitals and primary healthcare settings targeting the early detection of both deadly bacteria and certain cancers in the exhaled breath of patients. To find out more about Zenosense ( : ZENO), visit our website at www.zenosense.com. Statements in this news release that are not statements of historical fact are forward-looking statements, which are subject to certain risks and uncertainties. Forward-looking statements can often be identified by words such as "expects," "intends," "plans," "may," "could," "should," "anticipates," "likely," "believes" and words of similar import. Forward-looking statements are based on current facts and analyses and other information that are based on forecasts of future results, estimates of amounts not yet determined and assumptions of management. Actual results may differ materially from those expressed or implied by forward-looking statements due to a variety of factors that may or may not be foreseeable or within the reasonable control of the Company. Readers are cautioned not to place undue reliance on such forward-looking statements. Additional information on risks and other factors that may affect the business and financial results of the Company can be found in filings of the Company with the U.S. Securities and Exchange Commission, including without limitation the section entitled "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2015 filed on filed on May 23, 2016, and in Company reports filed subsequently thereto. Except as otherwise required by law, the Company disclaims any obligations or undertaking to publicly release any updates or revisions to any forward-looking statement contained in this news release to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based. Respective statements concerning the development of both MIDS Cardiac™ and other devices under development have been made based on information obtained from MIDS Medical Ltd. and / or Zenon Biosystem, which the Company believes to be accurate, but have not been independently verified.


News Article | February 16, 2017
Site: www.prnewswire.co.uk

Patient Care services are vastly improving with the infusion of innovative telemedicine application, new and leading edge therapies and remote patient monitoring services that are experiencing a boom worldwide. The healthcare sector as whole continues to evolve with the advancement of technologies, services and new therapies for companies such as Reliq Health Technologies Inc. (OTC: RQHTF) (TSX-V: RHT), Cellectar Biosciences, Inc. (NASDAQ: CLRB), Cytori Therapeutics, Inc. (NASDQ: CYTX), Zenosense, Inc. (OTC: ZENO), BioTelemetry, Inc. (NASDAQ: BEAT). Reliq Health Technologies Inc. (OTCQB: RQHTF) (TSX: RHT.V), a technology company focused on creating innovative mobile health (mHealth) and telemedicine solutions for Community-based Healthcare, is pleased to announce that it has signed an agreement with Paz Home Health LLC in Texas to provide Reliq's hardware and software solutions to their home care clients. Patient enrollment will begin in March 2017 with 500 Paz Home Health patients, building to over 10,000 patients and over $6 Million in recurring annual revenue in 2018. Read this full release and recent news releases for Reliq Health Technologies at http://marketnewsupdates.com/news/rqhtf.html "We are very pleased to be working with Paz Home Health to deliver high quality care to patients in the home," said Dr. Lisa Crossley, CEO of Reliq Health Technologies, Inc. "Reliq's remote patient monitoring system quickly and easily collects sophisticated health data from patients in their own homes. Our secure, cloud-based care collaboration platform provides the clinical care team, patient and family members with real-time access to patient health information including trends over time. This helps the care team identify patients whose condition is becoming unstable and intervene early, before a serious complication develops. Patients and their loved ones are able to clearly see how compliance with prescribed medication and lifestyle changes affect the patient's health measures, improving patient engagement and patient- and family-reported satisfaction. Reliq's virtual care platform was designed to reduce readmissions and improve health outcomes. Our technology allows patients to receive high quality care from the comfort of their own homes, reducing the cost of care delivery and increasing patient and family satisfaction." "Our mission at Paz Home Health is to provide peace of mind for patients and their loved ones," said Dayana Bermea, CEO. "We are excited to be working with Reliq Health to support our care providers in their day-to-day workflow, freeing up more time for patient care. Reliq Health's cloud-based portal will allow our clients' family members to access real-time information about their loved one's health status, care team and home visit schedule. Patients and their families can feel secure knowing that the Reliq Health system will continuously monitor the patient at home and summon emergency services if needed. At Paz Home Health we are always striving to provide our clients with best in class home healthcare." In other healthcare sector-related market performances and developments of note: Cellectar Biosciences, Inc. (NASDAQ: CLRB) closed up over 6% on Wednesday at $2.49 trading over 1.6 Million shares by the market close. Cellectar Biosciences, announced this month the advance online publication of an article in Nature Reviews Clinical Oncology. In addition, the company anticipates an oral presentation on its drug delivery platform at the Academic Surgical Congress on February 8, 2017, at the Encore Hotel, Las Vegas. Each publication increases our understanding regarding the unique tumor targeting ability of the company's phospholipid drug conjugates (PDCs) with fluorescent payloads. Cytori Therapeutics, Inc. (NASDQ: CYTX) closed up slightly on Wednesday at $1.99 trading over 1.4 Million shares by the market close. Cytori Therapeutics this week announced it has completed its acquisition of assets of privately held Azaya Therapeutics, Inc., a leader in the research, development and manufacturing of nanoparticle therapeutics (the "Acquisition"). The Acquisition provides Cytori with a proprietary liposomal nanoparticle technology platform that is intended to complement Cytori's leadership position in regenerative medicine and expand its pipeline with two promising nanoparticle oncology drugs. Zenosense, Inc. (OTCQB: ZENO) closed up over 47% on Wednesday at $0.65 by the market close well above the average daily trading volume. Zenosense, a healthcare technology company primarily focused on the development and commercialization of MIDS Cardiac™, a Point of Care ("POC") handheld device for the early detection of certain cardiac event biomarkers to significantly accelerate the triage, diagnosis, treatment and disposition of patients reporting chest pain and with suspected acute myocardial infarction (heart attack), announced last month that MIDS Medical Limited ("MML"), our 40% owned joint venture based at Sci-Tech, Daresbury, UK has submitted a UK Intellectual Property Office patent application for an additional MIDS detection method. BioTelemetry, Inc. (NASDAQ: BEAT) closed up on Wednesday at $25.10 trading over 700,000 shares by the market close. BioTelemetry is the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care. The company currently provides cardiac monitoring services, original equipment manufacturing with a primary focus on cardiac monitoring devices and centralized cardiac core laboratory services. DISCLAIMER: MarketNewsUpdates.com (MNU) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. MNU is NOT affiliated in any manner with any company mentioned herein. MNU and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. MNU's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. MNU is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed MNU has been compensated three thousand nine hundred dollars for news coverage of the current press release issued by Reliq Health Technologies Inc. by a non-affiliated third party. MNU HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE. This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MNU undertakes no obligation to update such statements.


News Article | October 28, 2016
Site: www.marketwired.com

DENVER, CO--(Marketwired - Oct 26, 2016) -  Blue Diamond Ventures Inc. ( : BLDV) reports that the company has successfully finalized an agreement to acquire the Verve Living Systems & ZENO InnPoint brands/trademarks along with the ongoing business and hospitality assets of Zeno Controls LLC, a New York based limited liability company. The ZENO wireless gateways and cloud solutions provide energy saving and management to the hospitality industry, while the VERVE Living Systems brand provides the sensors and guestroom control products. The VERVE product line includes 27 products, ranging from switches to thermostats, occupancy sensors, HVAC controls, lighting and load control. www.vervelivingsystems.com www.zenocontrols.com Josh Alper, CEO of Blue Diamond Ventures, commented, "Through this agreement, Blue Diamond becomes the first energy-management and in-room controls provider to support both EnOcean and ZigBee technologies, to deliver the most flexible wireless performance platform on the market. In addition to current markets of Zeno Controls and VERVE Living Systems, Blue Diamond will expand the VERVE Living System brand into the Cannabis Industry, with a VERVE branded Home Growing System that will leverage the VERVE self-correcting adaptive wireless "Hotel" technology, replacing the "Guest Comfort" with Plant Health. BLDV will place both VERVE and ZENO in the newly created d/b/a of Michigan Plant Technologies LLC, United Sustainable Technologies, that will be solely focused on sales to hospitality end-users and the development of the new residential grow products in the Cannabis space." In other company news, Blue Diamond announces that Clean 1st LLC, the owners of Cannabis Clean (www.cannabisclean.com) a 20% holding of BLDV, has closed several new large contracts to provide specialized and antimicrobial janitorial services to cannabis cultivators in Colorado. Clean 1st has in addition acquired a small existing janitorial service and is still actively seeking to hire additional personal to help keep up with the demand. Steve McMorrow, President of Clean 1st, and Josh Alper, CEO of BLDV, have met in Denver this past week to discuss expansion of the company's operational model to other markets in and outside of the USA. Cannabis Clean will be exhibiting at the upcoming MJ Daily Marijuana Show in Las Vegas on November 15th - 17th, 2016 and will be announcing plans for a new authorized dealer network. Now Brands, LLC (www.now-brands.com) the owners of Olde Imperial Mystic Hemp Vodka, a 40% holding of Blue Diamond Ventures Inc., has successfully completed the first production run of its triple gold medal award-winning Hemp infused Vodka. The product is now available in New York State via Now Brands distributor LNJ Brands. Blue Diamond Consulting LLC ( http://bd-suiteofservices.com/ ) has begun work on a community solar project in the Western New York. The company has been contracted as the owner's representative for a major development company in Buffalo, NY and will receive fees for its services. This will be our first solar project and will be an operational model that BLDV and BDC will seek to duplicate in other markets. In other consulting news, in addition to the solar projects above, Blue Diamond Consulting (BDC), has successfully completed its review of the California Lights Works Cannabis LED Lighting, and has signed a short-term consulting agreement with a Cannabis Greenhouse Systems. In addition, BDC has entered into a consulting agreement with a Canadian Cannabis Grower who has just received their pre-license from Health Canada. BDC will begin its service after the grower has completed its second round of funding to complete its 50,000-sq. foot cultivation center in Ontario. BDC has signed multiple clients pursuing marijuana licenses under the new laws in Michigan. "Blue Diamond Ventures Inc. has begun to successfully transform itself as I have envisioned, and put the main emphasis on the consulting services driving the other holdings," said CEO Josh Alper. In addition to the clients listed above, The BLDV business model relies on Blue Diamond Consulting to provide consulting services to our subsidiaries including Now-Brands LLC, Cannabis-Clean - Clean 1st LLC, Michigan Plant Technologies LLC. "Reflecting on my first six months as Chief Executive Officer, I am pleased with the progress BLDV has made, but recognize there is a lot of work left to be done to better position the company to enable it to be successful. I am confident that the Suite of Services that BLDV markets to the Cannabis Industry and beyond will be the key to this success," Mr. Alper stated. Blue Diamond Ventures, Inc. is in the process of scheduling a shareholder conference call to take place on Tuesday, November 22nd at 4:30 PM EST. More details concerning this event will be released soon. Included will be call-in information and the ability for shareholders to email any questions in advance to Mr. Alper. Blue Diamond Ventures, Inc. seeks to partner with individuals and companies that share a common synergy, mission, and vision to enable products/services that are produced, delivered and consumed utilizing fewer natural resources, providing a sustainable alternative to traditional products on the market today. As a diversified customer, centric Management / Holding Company; Blue Diamond Ventures, Inc. seeks opportunities in various markets and is driven by critical thinking and the scientific method. This press release contains forward-looking statements. Such forward-looking statements are subject to a number of risks, assumptions, and uncertainties that could cause the Company's actual results to differ materially from those projected in such statements. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly revise any forward-looking statements.


The invention concerns a method and a system for purposes of registering the position of a vehicle (1) in a defined region (3), wherein a digital map of the defined region (3) is created, having a defined coordinates system, wherein the digital map includes stationary reference features (T1) with a unique identifying feature, before digital images are recorded of at least a sub-region of the defined region (3), preferably of the whole defined region (3), for purposes of registering and detecting further reference features (T1, T2, T3), wherein stationary and/or temporary reference features (T2, T3) without unique identifying features are also registered and detected, and are added to the digital map and/or an associated buffer store, so that the absolute position of the vehicle (1) in the defined region (3) can subsequently be determined, in that a digital image of a portion of the defined region (3) is recorded by the vehicle (1), and in the digital image reference features (T1, T2, T3) are detected and optionally identified, wherein the determination of absolute position is undertaken on the basis of the stationary and/or temporary reference features (T1, T2, T3) that have been detected and optionally identified.


Patent
Zeno | Date: 2012-07-25

A crank mechanism (P) for bicycles, in particular racing bicycles on roads, unsurfaced roads or tracks, comprises a winch rod (1), pedaling means (4) coupled with an end (6) of the rod (1), and also an arm (13) of a connecting-rod (13) of which one end is rotatingly coupled with respect to said rod (1) in correspondence with said end (6) of the rod (1); the pedaling means (4) are rigidly fixed to an opposite end of said arm (13).


The present invention refers to an element (10, 110) for swimming pool grids (100). Said element (10, 110) is adapted to be connected to other elements in order to obtain a swimming pool grid (100), said swimming pool grids (100) being adapted to define a walking surface. Said element (10, 110) comprising:- a main body (11) which is developed along a first line (L1) and which defines a first plane (P1) corresponding to the walking surface of the grids (100);- at least one tooth (12) which protrudes from the main body (11) and is developed on the first plane (P1);- a connector (24) which is connected to the main body (11) and is adapted to removably connect the element (10, 110) to other elements (10, 110). Besides, the present invention refers to a swimming pool grid (100) comprising one or more of the elements (10, 110) according to the invention.


Patent
Zeno | Date: 2014-08-06

A leveler (10) for laying and leveling slabs, tiles and similar, comprising:- a support (60) which in turn comprises:- a base (62), adapted to provide support to at least two adjacent tiles (P, Q, S),- at least one leg (66) protruding from said base (62) and adapted to rest on a side of said at least two tiles (P, Q, S) so as to define a space between said at least two tiles (P, Q, S) and extending for a height greater than the thickness of the at least two tiles (P, Q, S),- at least two counteracting faces (75) developing at a predetermined distance from said base (62), said at least two counteracting faces (75) protruding laterally from said at least one leg (66);- a knob (12) comprising an annular main body (14) and at least two ramps (16) protruding from the inside of said main body (14), said two ramps (16) being adapted to be coupled to the at least two counteracting faces (75) of the support (60) when said knob (12) is coupled to the support (60).


Grant
Agency: National Science Foundation | Branch: | Program: SBIR | Phase: Phase II | Award Amount: 493.72K | Year: 2012

This Small Business Innovation Research Phase II project seeks to continue the development of a novel one-transistor memory device, which has both volatile and non-volatile functionality, through collaboration with a commercial foundry partner. Such memory combines the non-volatile memory's ability to retain information in the absence of power (such as Flash memory) and the fast access speed and reliability of a volatile memory (such as Static Random Access Memory (SRAM)). In addition to the memory cell development and optimization, a memory block will also be developed to initiate commercialization effort of the memory technology. The broader impact/commercial potential of this project is to enable power-efficient computing applications and mobile devices. For example, it can be used to reduce power consumptions in data centers. Data centers' annual energy consumption is estimated to be 150 billion kWh, about twice the capacity of the current US solar panel. A power-efficient memory such as the one proposed in this proposal can reduce the overall data centers' power consumption by up to 75%. Another application is to provide an integrated memory solution. Many electronic devices currently employ multiple types of memory, due to their own distinct characteristics. The proposed device will be able to combine the different types of memory into a single memory device, simplifying the manufacturing process for embedded memories.

Loading ZENO collaborators
Loading ZENO collaborators